H2S Activated Drug Release from Protein Cages.

The research article discusses the use of the gasotransmitter hydrogen sulfide (H2S) as a trigger for the controlled release of a cancer drug named Doxorubicin, which is enclosed in protein cages.

Protein Cages and Drug Release

• Protein cages, specifically horse spleen apoferritin, were used to enclose doxorubicin, a chemotherapy drug used to treat various types of cancer.
• The researchers utilized a gasotransmitter, hydrogen sulfide (H2S), as a chemical trigger to control the release of the drug.
• This drug delivery system proved to be stable at physiological pH and temperature, meaning it could potentially function effectively within a human body.

Mechanism of Drug Release

• H2S was used to initiate the drug release process. This method of controlled drug release was designed to avoid the disassembly of the protein shells in which the drug is stored.
• Sensitive to H2S, the drug release is further controlled by the strong interaction between sulfide and copper ions. Copper ions were used to precoordinate the doxorubicin within the protein cages. When H2S interacts with the copper ions, it triggers the release of the drug.

Effectiveness of the Drug

• Upon administration, the drug-induced toxicity specifically targets and kills cancer cells.
• According to the in vitro tests carried out, the antitumor effect of doxorubicin could be achieved by the activation of H2S, confirming the effectiveness of this novel drug delivery system.

Implications

• The study’s findings suggest that utilizing gasotransmitter H2S as a trigger for controlled drug release is effective and could potentially be used in treating various forms of cancer.
• The drug delivery system described in this research, using protein cages for storage and a gasotransmitter for activation, might pave the way for future advancements in the field of targeted cancer therapy.